What is GLSI's market cap?

$239.99M, based on the Nov 4 close of $16.35.

Does Greenwich LifeSciences pay a dividend?

No regular cash dividend has been paid in the last year.

How much of GLSI is sold short?

1.6M shares, 24.5% of float, as of Oct 15, 2026.

What sector is GLSI in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · GLSIHealthcarePharmaceuticals

Greenwich LifeSciences, Inc. (GLSI)

$16.35+2.70%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$15.92▲ 88.85% in range

Nov 3, 2025Low $7.85 · High $33.56Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Greenwich LifeSciences closed at $16.35 on Nov 4, up 2.70%, 51.3% below its 52-week closing high. Volume of 135.3K shares was 1.01× its 20-day average (close to normal).

Split-adjusted performance: +3.5% over one month, -29.1% over six months, +94.0% over one year.

Short interest was 1.6M shares at the Oct 15 settlement, down 1.8% from the prior report (24.5% of float, 10.7 days to cover).

Market cap$240.0M14.7M shares

Revenue · quarter$0.00—

Diluted EPS$-0.27—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range7.85 – 33.56−51.3% from high

Volume135.3K1.01× 20-day avg

Volatility · 60d92.1%Annualised

Short % of float24.5%10.7 days to cover

Net cash$8.9MCash $8.9M

Next earnings—Not scheduled

Split-adjusted performance

1W −10.7%1M +3.5%3M +14.8%6M −29.1%YTD −22.2%1Y +94.0%3Y +97.5%5Y −53.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum46

Revenue growth—

Net margin—

Value (low P/E)—

Size50

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short1.6M−1.8% vs prior

Days to cover10.7Settled Oct 15

% of float24.5%

Short vol. 10d69.8%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
GLSIGreenwich LifeSciences	$16.35	+2.70%	−29.1%	—	—	—	$240.0M
ABEOAbeona Therapeutics	$4.22	−0.71%	−29.8%	+2745.0%	−177.4%	—	$241.3M	Compare
LABStandard BioTools	$0.6160	+0.85%	−36.4%	−0.9%	69.6%	1.8	$243.1M	Compare
IMRXImmuneering	$3.76	+2.17%	−27.6%	—	—	—	$243.5M	Compare
LFCRLifecore Biomedical	$6.44	+0.31%	+29.8%	—	−20.9%	—	$244.1M	Compare
KRROKorro Bio	$16.62	+4.79%	+24.6%	−100.0%	—	—	$244.7M	Compare
CAMPCAMP4 Therapeutics	$3.74	−2.35%	−7.9%	+18.8%	−1884.8%	—	$234.7M	Compare
VNDAVanda Pharmaceuticals	$3.88	+3.47%	−47.8%	+24.1%	−32.3%	—	$234.6M	Compare
SIGASIGA Technologies	$3.15	+1.29%	−33.0%	−49.5%	30.4%	—	$226.3M	Compare

News about Greenwich LifeSciences

All news →

Greenwich LifeSciences Provides Update Regarding Form 10-K FilingGlobeNewswire Inc. · Jun 1, 2026Neutral Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026GlobeNewswire Inc. · Apr 23, 2026▲ Positive Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingGlobeNewswire Inc. · Apr 22, 2026▼ Negative Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026GlobeNewswire Inc. · Apr 20, 2026▲ Positive Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market PotentialGlobeNewswire Inc. · Apr 7, 2026▲ Positive

Quick answers

What does Greenwich LifeSciences do?: Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
What is GLSI's market cap?: $239.99M, based on the Nov 4 close of $16.35.
Does Greenwich LifeSciences pay a dividend?: No regular cash dividend has been paid in the last year.
How much of GLSI is sold short?: 1.6M shares, 24.5% of float, as of Oct 15, 2026.
What sector is GLSI in?: Healthcare, in the Pharmaceuticals industry.

About Greenwich LifeSciences

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

HQ: Stafford, TX13 employeesListed Sep 25, 2020greenwichlifesciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology